⚖️💊❌ U.S. Judge Upholds FDA Ban On Compounded Copies Of Lilly’s Weight-Loss Drugs 🔹 Summary: A U.S. federal judge has upheld the FDA’s decision to remove Eli Lilly’s Zepbound and Mounjaro from the drug shortage list, blocking compounding pharmacies from making cheaper copies. The ruling, a blow to patients and compounders, reinforces Lilly’s control over its blockbuster diabetes and weight-loss drugs amid surging demand. 🔹 Key Points: • Compounding pharmacies were forced to stop producing copies of Zepbound and Mounjaro as of March 19. • The court rejected claims that the FDA relied solely on Lilly’s input to assess drug shortages. • A similar legal challenge over compounded copies of Novo Nordisk’s Ozempic and Wegovy is still pending. • Compounders argue the FDA’s determinations hurt patient access and favor large drugmakers. • Lilly and the FDA have not yet commented on the court’s sealed ruling. @CMEActiveTrader Tickers Of Interest: $NQ $ES $YM $ZN $GC Tickers Of Interest: $LLY $NVO $USD $XLV $IBB $PFE $MRK $AMGN $AZN